{
  "docId": "019de076-f978-76c3-9c95-6b6ce7102162",
  "docSlug": "c02a1d1cb7557bc430cc8dc61cd27097",
  "documentTitle": "CG Oncology | IPO Presentation Deck | 45 slides",
  "authorId": "cg-oncology",
  "authorName": "CG Oncology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 28,
  "pageCount": 45,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a hierarchical tree structure to map patient risk categories to specific clinical trial programs (PIVOT-006, CORE-008, BOND-003, CORE-001).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/28",
  "deckHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162",
  "deckJsonHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json",
  "deckAnchorHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Clinical trial program mapping to patient segments",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2144a2e2-9a85-4137-8b7d-2970cdae2ad7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.26
      },
      "kind": "diagram",
      "text": "NMIBC (75%) (Non-Muscle Invasive Bladder Cancer)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14684f97-10b8-4e48-9727-e5c88dce3553",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "legend",
      "text": "Current Program (black box) vs Planned Studies (orange box)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8acf6a0-c762-413b-b4ca-8eb269188e00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Intermediate Risk (30%) vs High Risk (40%)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6bcf64c-06ae-4c29-bc1f-6dadb3b07f71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "All Bladder Cancer (U.S. Incidence ~82,000 Patients/Year; Prevalence ~725,000 Patients)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a54263f4-e20f-4ca2-b6cf-e7527130e34a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Focused Execution Towards Becoming the Leader in High-Risk and Intermediate-Risk Markets with Multi-Billion Dollar Potential",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed813e15-57a0-4bc9-940f-836aa200e7a1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "40380a79-e666-450f-a401-85ba5066ec9e",
      "evidence": "chart/bar-vertical: Clinical trial program mapping to patient segments",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "6366e858-9526-4932-811c-df6bd1a73b25",
      "evidence": "Hierarchical breakdown of bladder cancer patients by risk and treatment status.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed",
      "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').",
      "position": 0,
      "objective": "What are the consequences of not adopting Cretostimogene?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}